Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

NCT03440788 UNKNOWN

The goal of this is study is focusing on assessment of patient-reported outcomes in terms of quality of life (QoL) and symptom profile as well on evaluation of clinical efficacy and safety of BV in patients with refractory/resistant HL in a real-world setting.

Details

Lead sponsor	Multinational Center for Quality of Life Research, Russia
Status	UNKNOWN
Enrolment	70
Start date	Mon Apr 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Relapsed or Refractory Hodgkin's Lymphoma

Interventions

• Brentuximab Vedotin

Countries

Russia